Last reviewed · How we verify
ESCALATED BEACOPP
Beacopan is a monoclonal antibody that targets CD137, a member of the tumor necrosis factor receptor superfamily.
Beacopan is a monoclonal antibody that targets CD137, a member of the tumor necrosis factor receptor superfamily. Used for Hodgkin lymphoma.
At a glance
| Generic name | ESCALATED BEACOPP |
|---|---|
| Also known as | BLEOMICINE TEVA, VEPESID, DOXORUBICINE TEVA, ENDOXAN, VINCRISTINE TEVA |
| Sponsor | Ospedale Santa Croce-Carle Cuneo |
| Drug class | Monoclonal antibody |
| Target | CD137 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CD137 is expressed on activated T cells and plays a role in the regulation of immune responses. By targeting CD137, Beacopan aims to enhance anti-tumor immune responses.
Approved indications
- Hodgkin lymphoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- FIL Study on ABVD DD-DI as Upfront Therapy in HL. (PHASE3)
- Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma (PHASE3)
- HD21 for Advanced Stages (PHASE3)
- Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma (PHASE3)
- Prognostic Significance of ctDNA in HL
- S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma (PHASE2)
- Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma (PHASE2)
- Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ESCALATED BEACOPP CI brief — competitive landscape report
- ESCALATED BEACOPP updates RSS · CI watch RSS
- Ospedale Santa Croce-Carle Cuneo portfolio CI